Frameless linac-based radiosurgery for benign intracranial tumors treated with HyperArc: analysis of tumor control and toxicity - Top-Institutions - MDSpire

Frameless linac-based radiosurgery for benign intracranial tumors treated with HyperArc: analysis of tumor control and toxicity

  • By

  • Whitney S. Hotsinpiller

  • Evan M. Thomas

  • Ian Tsekouras

  • Richard A. Popple

  • Markus Bredel

  • Christopher D. Willey

  • Barton L. Guthrie

  • James M. Markert

  • Kristen O. Riley

  • John B. Fiveash

  • Drexell Hunter Boggs

  • October 21, 2025

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Radiation Oncology
    • Neuro-oncology
    • Stereotactic Radiosurgery

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Radiation Oncology
    • Neurosurgery
    • Stereotactic Radiosurgery

  • #3

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Radiation Oncology
    • Neuro-oncology
    • Medical Physics

  • #4

    Stanford University Medical Center
    Stanford University Medical Center

    Stanford, CA

    Key Differentiators

    • Radiation Oncology
    • Neurosurgery
    • Biomedical Engineering

  • #5

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Radiation Oncology
    • Neurosurgery
    • Neuro-oncology

Original Source(s)

Frameless linac-based radiosurgery for benign intracranial tumors treated with HyperArc: analysis of tumor control and toxicity

  • by Whitney S. Hotsinpiller, Evan M. Thomas, Ian Tsekouras, Richard A. Popple, Markus Bredel, Christopher D. Willey, Barton L. Guthrie, James M. Markert, Kristen O. Riley, John B. Fiveash, Drexell Hunter Boggs

  • October 21, 2025

Related Content

Neoadjuvant Radiotherapy with Camrelizumab as a Chemotherapy-Sparing Strategy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Phase II Trial (ESOCORT-NIRT)

Evaluation of Radiation Therapy Protocols Before and After Biodegradable Hydrogel (SpaceOAR) Administration to Mitigate Rectal Toxicity in Prostate Cancer Patients Receiving Carbon Ion Radiotherapy

Assessment of Organs at Risk (OARs) During Whole-Breast Radiation Therapy: A Comparative Analysis of Prone and Supine Positions with Deep Inspiration Breath-Hold Techniques from a Prospective Study Subgroup